Lucy Scientific Discovery Inc.

LSDI

CA54960E2033

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7597 ^USD	-12.68%		-32.17%	-70.33%

Mar. 06	Lucy Scientific Discovery Inc. cancelled the acquisition of BlueSky Wellness Inc.	CI
Feb. 27	Lucy Scientific Discovery Inc. Announces Expiration of Term Assad J. Kazeminy, Chief Scientific Officer	CI

Lucy Scientific Discovery Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023

November 13, 2023 at 04:30 pm EST

Lucy Scientific Discovery Inc. reported earnings results for the first quarter ended September 30, 2023. For the first quarter, the company reported net loss was USD 2 million compared to USD 1.37 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.13 a year ago.

Latest news about Lucy Scientific Discovery Inc.

Lucy Scientific Discovery Inc. cancelled the acquisition of BlueSky Wellness Inc.	Mar. 05	CI
Lucy Scientific Discovery Inc. Announces Expiration of Term Assad J. Kazeminy, Chief Scientific Officer	Feb. 27	CI
Lucy Scientific Discovery to Implement 1-for-10 Reverse Stock Split	Feb. 16	MT
Lucy Scientific Discovery Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
Lucy Scientific Discovery Inc. announced that it expects to receive $1.8 million in funding	Dec. 11	CI
Lucy Scientific Discovery Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 13	CI
Lucy Scientific Discovery Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-13	CI
Lucy Scientific Discovery Inc. entered into an agreement to acquire BlueSky Wellness Inc.	23-09-11	CI
Lucy Scientific Discovery to Buy High Times Intellectual Property	23-09-07	MT
Certain Warrants of Lucy Scientific Discovery Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2023.	23-08-06	CI
Certain Stock Options of Lucy Scientific Discovery Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2023.	23-08-06	CI
Certain Common Shares of Lucy Scientific Discovery Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2023.	23-08-06	CI
Lucy Scientific Discovery Inc. cancelled the acquisition of Pasithea Therapeutics Corp..	23-07-19	CI
Lucy Scientific Discovery Executive Chairman Named CEO	23-07-13	MT
Lucy Scientific Discovery Inc. Announces Chief Executive Officer Changes	23-07-13	CI
Lucy Scientific Discovery Introduces New Sleep Aid Product	23-07-11	MT
Lucy Scientific Discovery Reiterates Proposal to Acquire Pasithea Therapeutics	23-06-29	MT
Pasithea Therapeutics Confirms Unsolicited Takeover Proposal From Lucy Scientific Discovery	23-06-06	MT
Lucy Scientific Discovery Proposes to Acquire Pasithea Therapeutics	23-06-05	MT
Lucy Scientific Discovery Inc. made a proposal to acquire Pasithea Therapeutics Corp. for $22.2 million.	23-06-04	CI
Lucy Scientific Discovery Inc.'S Functional Amanita Line Now Available for Purchase Through Retail Channels	23-05-22	CI
Wall Street Set to Open Higher; Investors Look to Powell Speech for Fed Action Hints	23-05-19	MT
US Futures Trend Higher Pre-Bell Ahead of Powell Speech	23-05-19	MT
Top Premarket Gainers	23-05-19	MT
Lucy Scientific Discovery Working With TheraPsil to Research, Expand Access to Psychedelic Psilocybin for Patients in Canada	23-05-18	MT

Chart Lucy Scientific Discovery Inc.

Duration

Period

More charts

Company Profile

Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUCY SCIENTIFIC DISCOVERY INC.	-70.33%	1.34M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals